

Fate Therapeutics to Present at Oppenheimer & Co. 26th Annual Healthcare Conference

SAN DIEGO, Dec. 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders, announced today that Scott Wolchko, President and Chief Executive Officer, will be presenting at the Oppenheimer & Co. 26th Annual Healthcare Conference at 2:10 p.m. ET on Wednesday, December 9, 2015 in New York City.

A live webcast of the presentation will be available through the investor relations section of the Company's website at <u>www.fatetherapeutics.com</u>. Following the live webcast, an archived replay will be available on the Company's website for 30 days after the conference.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapeutics for the treatment of cancer and immune disorders. The Company's cell-based product pipeline is comprised of off-the-shelf immuno-oncology therapeutics, including NK- and T-cell-based candidates derived from induced pluripotent cells, and immuno-regulatory therapeutics, including hematopoietic cell-based candidates for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing auto-reactive T cells of patients with auto-immune disorders. Its adoptive cell therapy candidates are based on the Company's novel *ex vivo* cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit <u>www.fatetherapeutics.com</u>.

CONTACT: Jesse Baumgartner, Stern Investor Relations, Inc.

212.362.1200, jesse@sternir.com



Source: Fate Therapeutics, Inc

News Provided by Acquire Media